Skip to main navigation Skip to search Skip to main content

Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus

  • A. Boyd
  • , K. Lacombe*
  • , P. Miailhes
  • , J. Gozlan
  • , P. Bonnard
  • , J. M. Molina
  • , C. Lascoux-Combe
  • , L. Serfaty
  • , E. Gault
  • , M. Desvarieux
  • , P. M. Girard
  • *Corresponding author for this work
  • Institut national de la santé et de la recherche médicale
  • Sorbonne Université
  • Hospices civils de Lyon
  • Centre de recherche des Cordeliers
  • Hôpital Tenon
  • Université Paris Cité
  • Hôpital Avicenne
  • Université Paris 13
  • Mailman School of Public Health

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Virological interactions of hepatitis B (HBV), hepatitis C (HCV) and hepatitis D (HDV) viruses in HIV-infected patients have been poorly characterized especially under treatment influences. Undetection rates of hepatitis viruses were longitudinally analyzed in a 3-year cohort of 308 HIV-HBV co-infected patients and compared using Generalized Estimating Equation models adjusted for age, HIV-RNA, CD4 cell-count and antiviral treatment. Chronic hepatitis co-infection in HIV-infected patients (age years, SD) was: 265 HBV (40.7, 8.2); 19 HBV-HCV (39.7, 4.1); 12 HBV-HDV (35.2, 9.9); 12 HBV-HCV-HDV (39.2, 5.2). At inclusion, treatment with lamivudinetenofovir was not significantly different between co-infection groups. HBV suppression was significantly associated with HDV (aOR = 3.85, 95%CI 1.13-13.10, P = 0.03) and HCV tri-infection (aOR = 2.65, 95%CI 1.03-6.81, P = 0.04), but marginally associated with HIV-HBV-HCV-HDV (aOR = 2.32, 95%CI 0.94-5.74, P = 0.07). In quad-infection, lower HDV-undetectability (vs HIV-HBV-HDV, P = 0.2) and higher HCV-undetectability (vs HIV-HBV-HCV, P = 0.1) were demonstrated. The degree of HBV suppression varied between visits and co-infection groups [range of aOR during follow-up (vs HIV-HBV co-infection): HIV-HBV-HCV = 2.23-5.67, HIV-HBV-HDV = 1.53-15.17]. In treated co-infected patients, HDV expressed continuous suppression over HCV- and HBV-replications. Peaks and rebounds from undetectable hepatitis B, C andor D viremia warrant closer follow-up in this patient population. HDV-replication was uncontrolled even with antiviral treatment. © 2009 Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)65-76
Number of pages12
JournalJournal of viral hepatitis
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 2010
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adult
  • Anti-HIV Agents/therapeutic use
  • CD4 Lymphocyte Count
  • Comorbidity
  • Female
  • HIV Infections/complications
  • HIV-1/isolation & purification
  • Hepacivirus/isolation & purification
  • Hepatitis B/complications
  • Hepatitis B virus/isolation & purification
  • Hepatitis C/complications
  • Hepatitis D/complications
  • Hepatitis Delta Virus/isolation & purification
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Treatment Outcome
  • Viral Load
  • Viremia

Fingerprint

Dive into the research topics of 'Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus'. Together they form a unique fingerprint.

Cite this